When weighing clinical efficacy and safety, pembrolizumab combined with chemotherapy emerges as a strong first-line treatment option for R/M HNSCC patients without PD-L1 selection, while nivolumab stands out as the optimal second-line therapy. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.